Tag:

Aprecia Pharmaceuticals announced the U.S. availability of its Spritam (levetiracetam) tablets...The epilepsy medication is the first tablet made using the company’s ZipDose 3D printing technology to be approved by the Food and Drug Administration. It is designed to dissolve with a sip of liquid, easing the process of taking medication for patients with difficulty swallowing...

3-D printed medicine specialist Aprecia Pharmaceuticals announced that it has completed a $35 million financing round...The move should help...Aprecia commercialize the first FDA-approved 3-D printed drug, Spritam (levetiracetam), a reformulated, easy-to-swallow med for the treatment of epilepsy. The launch is expected to occur in the first half of this year...Aprecia has exclusive rights to utilize Powder-liquid 3DP, a 3-D printing technology developed by MIT in the 1980s. The technique enables the company's ZipDose delivery platform. By printing a tablet consisting of layers of powder, Aprecia drugs can achieve a high degree of dissolvability in liquid. That means dosages as high as 1,000 mg will disintegrate in liquid...The new manufacturing methodology could also facilitate decentralized drug manufacturing and customization of medications to the needs of individual patients.

Food and Drug Administration has approved the first three-dimensional printed oral drug product, Spritam (levetiracetam), from Aprecia Pharmaceuticals,…indicated as adjunctive therapy for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and children with epilepsy…was developed with Aprecia's proprietary ZipDose technology, which uses three-dimensional printing to create a porous formulation...that disintegrates rapidly...